study question: The 14th European IVF-monitoring (EIM) report presents the results of medically assisted reproduction treatments including assisted reproductive technology (ART) cycles and intrauterine insemination (IUI) cycles initiated in Europe during 2010: are there changes in the trends compared with previous years? summary answer: Despite some fluctuations in the number of countries reporting, the overall number of ART cycles has continued to increase year by year, and while pregnancy rates in 2010 remained similar to those reported in 2009, the number of transfers with multiple embryos (three or more) further declined.
Introduction
This report is the 14th annual publication by the European IVF Monitoring (EIM) Consortium on behalf of the European Society of Human Reproduction and Embryology (ESHRE) with respect to European data on treatments with assisted reproductive technology (ART) and intrauterine insemination (IUI). The 13 previous reports, also published in Human Reproduction (ESHRE, 2001a (ESHRE, , b, 2002 (ESHRE, -2008 Nyboe Andersen et al., 2009; de Mouzon et al., 2010 de Mouzon et al., , 2012 Ferraretti et al., 2012 Ferraretti et al., , 2013 (http://www.eshre.eu/Data-collection-and-trials/ Consortia/EIM/Publications.aspx), covered treatment cycles from 1997 to 2009. As in the last reports, the printed version contains the four most significant tables. Additionally, a total of 19 supplementary tables are available online, making the whole report consistent with publications from previous years. In the Results section, these tables are referred to as Supplementary data, Tables SI -SXIX. The main results of this report were presented at the annual ESHRE congress in London, July 2013, and for the first time three figures are included.
Materials and Methods
Data on ART were collected from 31 European countries, covering IVF, ICSI, frozen embryo replacement (FER), egg donation (ED), in vitro maturation (IVM), pooled data on preimplantation genetic diagnosis (PGD) and preimplantation genetic screening (PGS) as well as frozen oocyte replacements (FOR) . In addition to ART, data on IUI using husband/partner's semen (IUI-H) and donor semen (IUI-D) were also included.
The report includes treatments started between 1 January 2010 and 31 December 2010. Data on pregnancy outcomes are derived from follow-up of the cohort treated during this time period (calendar year 2010).
The method of reporting data in 2010 was similar to that used in the previous years, making almost all tables comparable. One extra table with an overview of all countries has been added in the current report (Supplementary data, Table SI ). Although some titles of the tables were changed, their content remained similar to that of previous years.
After revision of the data collection forms, a few additional pieces of information were collected regarding registry characteristics (validation process, public access to individual clinical data and financial support) and regarding the number of fresh IVF cycles performed with semen donation or surgically obtained partner's semen.
In addition, ED cycles were divided into fresh and frozen replacements and data on embryo donation were also collected.
To clarify what kind of information was needed, extra footnotes were added. The main focus of the EIM reports is to cover the huge variety of treatments in Europe with all the different regulations and laws behind them.
The questionnaire was sent out to the co-ordinator of each participating country in April 2012. Data were directly entered in an online ESHRE computer system by each country co-ordinator. Data analysis was performed in ESHRE's central office by V. Goossens.
A software tool for an automated analysis including trend analysis and consistency controls is under construction. This will also make the recording and analysis of the data less time consuming.
After the first tables had been created each participating country had the opportunity to correct the data in March 2014.
As is evident from the tables, the only complete data reported from all countries were on the number of aspirations and the number of centres.
Three countries were able to provide data for the 2009 report but failed to do so for the 2010 data collection. Four countries did not provide any data for two consecutive years (2009 and 2010) . No 'new' country provided data.
The number of pregnancies and the number of transfers were reported by all but one country (Czech Republic). Registries from six countries did not provide data on initiated cycles and registries from five countries did not provide data on deliveries; in addition, several countries showed a high percentage of pregnancies that are lost to follow-up.
Therefore, complete outcome data were only available on the pregnancy rate per aspiration, while some of the more reliable indicators of treatment success (clinical pregnancies and deliveries per initiated cycle) cannot be reported correctly and comparing countries should be done with some caution.
Total values (in terms of numbers and percentages) presented in the tables refer to those countries where all data have been reported, as underlined in the footnotes.
Definitions refer to the glossary of ART terminology published jointly by the International Committee for Monitoring Assisted Reproductive Technology (ICMART) and the World Health Organization (Zegers-Hochschild et al., 2009) .
Results

Participation
The present report includes data from 31 of 47 European countries (Supplementary data, Table SI) .
In contrast to the 2009 report, three countries were not able to send data: Croatia, Cyprus and Latvia (contributing in 2009 with 3029 cycles all together). Turkey (one of the main contributors in 2008 with 107 clinics and 43 928 cycles), Bosnia, Estonia and Albania reported in 2008 but for 2 years these countries have not contributed to the ESHRE EIM report.
The proportion of clinics reporting data was 82.5% of all clinics practicing ART (85.2% in 2009) (Table I Treatment cycles in IVF and ICSI refer to initiated cycles. For Austria, Belgium, France, Germany and Iceland treatment cycles refer to aspirations. For Belgium, the Czech Republic and Germany the total number of initiated cycles was only available for IVF and ICSI together, being 20 572, 12 864 and 55 687, respectively. For Austria in 379 cycles it is not known whether IVF or ICSI was performed, these cycles were included in 'ICSI'. For the Czech Republic, no distinction between IVF and ICSI is made. All cycles are counted as ICSI. For Belgium there are 824 extra aspiration cycles for which it is not known whether IVF or ICSI was performed. Treatment cycles in FER refer to thawings. For Finland, Hungary and the Netherlands treatment cycles refer to transfers. Treatment cycles in PGD contain both fresh and frozen cycles and refer to initiated cycles in the fresh cycles and aspirations in the frozen cycles. Treatment cycles in ED refer to donation cycles and contain fresh and frozen cycles. ED fresh: for France and Iceland treatment cycles refer to aspirations. ED frozen: for France, Iceland, Kazakhstan, Spain, Sweden and the UK treatment cycles refer to aspirations. Treatment cycles in IVM refer to aspirations. Treatment cycles in FOR refer to thawings, for Finland it refers to transfers. Women of reproductive age and population were found at the following link: http://www.census.gov/population/international/data/idb/region.php. IVF, in vitro fertilization; IUI, intrauterine insemination; ICSI, intracytoplasmic sperm injection; FER, frozen embryo replacement; ED, egg donation; IVM, in vitro maturation; PGD, preimplantation genetic diagnosis; FOR, frozen oocyte replacements (FOR). coverage reached 100% (Table I, Supplementary data, Table SIV ). Switzerland, Moldova and Ireland were each able to report data from all centres but one. In France and Germany .90% of the centers participated in this report. In Germany this is the result of a fundamental change in the structure of the data-collection and data-analysis in 2012 and 2013. In France three clinics sent data too late to be included in the national report.
Participation was very low in Greece (18%), and limited in Lithuania (25%), Kazakhstan (30%) and in Bulgaria (33%). Among the countries with the largest populations in Europe, the proportion of participating centers was 100% in Italy and UK, 97% in France, 92% in Germany, 64% in Spain (66% in 2009) and 62% in Russia (72% in 2009).
Comparing the numbers of countries which provided data in 2009 and 2010 the number of registered IVF + ICSI cycles increased from 383 439 to 385 901 (0.6%).
The total number of registered cycles (IVF + ICSI + FER) increased from 482 590 to 496 191 (2.8%).
Reporting methods and size of the clinics
Among the 16 countries with complete registration and reporting to EIM (Supplementary data, Tables SIII and IV), national registration was compulsory for 14 countries (11 held by a National Health Authority and 3 by a Medical Organization) and voluntary for 2 countries (1 held by a Medical Organization and 1 by a National Health Authority).
Seven registers were based on individual forms, i.e. cycle-by-cycle data.
In the 15 countries with partial registration and reporting to EIM, 13 registers were voluntary and 2 compulsory. Two were held by a National Health Authority, 11 by a Medical Organization and 2 by personal initiative; only 3 countries collect cycle-by-cycle data.
Thirteen countries (Austria, Belgium, Finland, France, Germany, Hungary, Italy, Poland, Serbia, Spain, Sweden, Switzerland and the UK) reported some kind of data validation process. Public access to individual clinic data was available only in six countries: Hungary, Ireland, Macedonia, Romania, Spain and the UK. Public (+ industry or professional society) financial support was present in 19 countries, while in 12 countries (Bulgaria, Germany, Iceland, Ireland, Lithuania, Montenegro, Poland, Portugal, Serbia, Slovenia, Switzerland and the UK) all the expenses were covered by the centers themselves.
The distribution of clinics according to the number of cycles varied considerably among the countries (Supplementary data, Table SII ). For instance, small clinics, providing ,100 cycles annually, accounted for 5 out of 10 reporting centers in Romania (50%), 10 of 29 in Poland (35%) and 68 of 202 in Italy (34%). Large clinics performing .1000 cycles a year constituted 12 of 18 (67%) in Belgium, 2 of 3 (67%) in Slovenia and 7 of 13 (54%) in the Netherlands.
Number of treatment cycles per technique and availability
In total, 550 296 cycles were reported (Table I) , 12 833 more than in 2009 (+2.4%).
The 398 765 fresh cycles reported in 2010 included 125 994 (32%) IVF cycles and 272 771 ICSI (68%) cycles. For 10 years an increase in the proportion of ICSI to IVF was described. Since 2008 a plateau seems to be established ( Fig. 1) .
Among the fresh aspirations, 19 countries reported 10 773 of 218 276 cycles performed with donor semen (4.9%) and 20 countries reported 14 200 of 239 879 cycles performed with surgically obtained partner's semen (5.9%).
FER was performed in all countries but Moldova and Serbia, with a total of 114 593 cycles reported (+10 440 compared with 2009). Overall, the proportion of FER cycles to 'fresh' cycles was 28.0% (26% in 2009), but in some countries the proportion was much higher: 43% in Switzerland, 32% in Sweden, 29% in Poland and 40% in Finland. Table II shows pregnancy and delivery rates per aspiration for IVF and ICSI, and pregnancy and delivery rates per thawing for FER. Four countries (Czech Republic, Hungary, Lithuania and Romania) did not provide data on deliveries. Two countries (Austria and the Netherlands) provided only total cumulative deliveries after IVF and ICSI combined. Thus, the mean pregnancy and delivery rates were computed for countries providing the relevant information.
Pregnancies and deliveries after treatment
There were significant national variations in clinical outcomes. On average, pregnancy rates per aspiration were 29.2% (+0.3% compared with 2009) and 28.8% (28.7% in 2009) for IVF and ICSI, respectively, and 20.3% per thawing for FER (20.6%).
As shown in Supplementary data, Tables SXIII and XIV, several countries experienced difficulties in gathering full pregnancy outcome data. Overall, the pregnancies lost to follow-up starting from the stage of clinical pregnancy were 7.3% for IVF and ICSI (7 767/106 662) and 6.5% for FER (1 446/22 382).
The mean delivery rates per aspiration for IVF, ICSI and FER (per thawing) were 22.4, 21.1 and 14.1%, respectively (Table II) . These figures represent the actual recorded deliveries, even though a number of deliveries may have occurred in the lost to follow-up group. A detailed account of numbers of cycles, aspirations, transfers, pregnancies, deliveries and the corresponding rates per technique in each country are reported in Supplementary data, Table SV for IVF, Supplementary data, Table SVI for ICSI and Supplementary data, Table SVII for FER.
The numbers of documented pregnancy losses (miscarriages) were reported by 24 countries for IVF and ICSI and by 22 countries for FER (Supplementary data, Tables SXIII and XIV). In these countries, the rates varied from 9.9 to 23.0% for fresh cycles (mean of 17.3%) and from 0 to 33.3% for FER (mean of 21.7%).
The figures may be underestimated because of pregnancies lost to follow-up.
In the nine countries with complete follow-up, the figures were 20.3% for fresh cycles and 25.3% for FER.
ED was reported by 20 countries (Supplementary data, Table SVIII ). In most of the countries where data were not reported, this technique was not allowed. Since last data collection (2009) the donor cycles (aspirations) and the recipient cycles (transfers) were divided into fresh or frozen/thawed cycles.
Frozen/thawed cycles include cycles after oocyte as well as embryo cryopreservation. The mean pregnancy rate was 47.4% in fresh transfers and 33.3% in thawed transfers. In total, 8735 clinical pregnancies resulted from 20 357 embryo transfers (excluding the Czech Republic) with a pregnancy rate of 42.9% per transfer (42.3% in 2009). The mean delivery rates were 29.4% per transfer and 35.1% per donation in the countries reporting deliveries. The pregnancies lost to follow-up were 1018 (11.6%).
Twelve countries reported data on embryo donation: 1420 transfers were performed, with 490 pregnancies (34.5%) and 347 deliveries (24.4%).
In total, 120 634 infants were recorded as having been born as a consequence of IVF, ICSI, FER, ED and PGD in the 27 countries where the reporting included newborns (Table II) .
Of the 120 634 ART infants, 94 609 (78.4%) were born after IVF/ICSI fresh cycles, 17 689 (14.7%) after FER, 7302 (6.0%) after ED and 1034 (0.9%) after PGD.
In Finland, Iceland and Switzerland, one of three ART infants was born after FER.
In the countries with 100% coverage for the relevant data, the percentage of babies conceived through ART of the national births varied from 1.7% in Italy and 1.8% in Montenegro to 5.9% in Denmark. More details are provided in Supplementary data, Table SIV , showing that the percentage of ART babies was .3.0% in the Nordic countries.
Age distribution
The age distribution of women treated with IVF and ICSI varied across countries (Supplementary data, Tables SIX and SX). The highest percentages of women aged 40 years or more were found in Greece, Italy and Switzerland, whereas the highest percentages of women aged 34 years or less were found in Kazakhstan, Poland and Ukraine.
As expected, pregnancy rates associated with IVF and ICSI decreased with advancing age. The same trend was seen for delivery rates.
FER cycles (Supplementary data, Table SXI ) included a relatively higher percentage of young women (≤34 years) and, as in fresh cycles, pregnancy and delivery rates decreased with age. In ED cycles (Supplementary data, Table SXII), the age of the recipient was 40 years or more in 58.7% of cases on average, and few countries reported ,40%: Slovenia (37.5%), Romania (36.8%), Hungary (34.3%) and Sweden (10.5%). Pregnancy and delivery rates in oocyte recipients were comparable across different age groups. Table III summarizes the number of embryos transferred after IVF and ICSI combined. The total proportion of single embryo transfers (SETs) was 25. 7% (24.2% in 2009 and 22.4% in 2008) . Double embryo transfers (DETs) occurred in 56. 7% (57.7% in 2009 and 53.2% in 2008) ; triple embryo transfers in 16. 1% (16.9% in 2009 and 22.3% in 2008) and four or more embryos were transferred in 1.5% (1.2% in 2009 and 2.1% in 2008).
Number of embryos transferred and multiple births
Information on numbers of elective single transfers is not yet available. As shown in Table III , major differences were seen between countries concerning the number of embryos transferred. In 2010, three countries reported an SET rate of over 50% (Belgium 50.4%, Finland 67.5% and Sweden 73.3%).
The proportion of triple or more embryo transfers ranged from 0 in Sweden and Iceland and 0.2% in Finland to ≥40% in Bulgaria, Greece, Italy, Lithuania, Moldova, Montenegro, Romania and Serbia. Within these countries, the transfer of four or more embryos ranged from 0 in 12 countries (and up to 2% in 5 countries) to 20.8% in Romania.
In FER cycles, the proportion of single, double, triple and four or more embryo transfers were 36.8, 53.2, 9.6 and 0.4%, respectively. In ED, the figures were 19.7, 70.2, 9.5 and 0.6%.
In fresh IVF/ICSI cycles, the percentages of multiple deliveries were 19.6% for twins (19.4 in 2009, 20.7% in 2008 and 21.3% in 2007) ART in Europe, 2010
After FER, the percentages were 12.5% for twins (12.7% in 2009, 13.4% in 2008 and 13.1% in 2007) and 0.3% for triplet deliveries (also 0.3% in 2009, 2008 and 2007) .
Additional data on pregnancy outcome, singleton and multiple deliveries are provided in Supplementary data, Tables SXIII and SXIV. In ED, of 5763 deliveries with known data on multiplicity, 1430 were twins (24.8%) and 32 were triplets (0.6%) (data not presented in tables).
Perinatal risks and complications
Supplementary data, Table SXV summarizes the occurrence of preterm deliveries according to the number of newborns. Data were available from 17 countries. These show that the risk of extreme preterm birth (gestational weeks 20-27) remained stable from 1.1% (0.9% in 2009) for a singleton delivery to 3.3% (3.0% in 2009) for twins and 12.3% (13.6% in 2009) for triplets. The same trend was noted for very preterm birth (28 -32 weeks), from 2.4 to 10.4 and 31.0%, respectively.
Term delivery (37+ weeks) rates were 88.0% for singleton, 46.3% for twins and only 9.5% for triplets.
Ovarian hyperstimulation syndrome (OHSS) was reported in 25 of the 31 countries (Supplementary data, Table SXVI ). In total, 1500 cases of OHSS were recorded, corresponding to a prevalence of 0.3% (0.8% in 2009) of all stimulated cycles in the countries reporting the data. The table also includes data on the incidence of other adverse outcomes, such as bleeding (641 cases), infection (53 cases) and fetal reductions (441 cases). Maternal death was reported in two cases (one in 2009).
PGD/PGS
PGD/PGS activity, recorded from 17 countries (15 in 2009), involved 6399 cycles, 5384 aspirations, 4070 embryo transfers, 1352 pregnancies (25.1% per aspiration) and 957 deliveries (17.8% per aspiration), the main contributor being Spain with 2743 cycles. More complete data and detailed analysis of PGD/PGS in Europe are published separately by ESHRE's PGD Consortium (Moutou et al., 2014) .
In vitro maturation
IVM was recorded in 10 countries (Table I) . A total of 493 aspirations (1334 in 2009 and 562 in 2008) and 314 transfers were recorded, resulting in 69 pregnancies and 43 deliveries. Russia accounted for 45% of cycles and 21% of deliveries.
Frozen oocyte replacement
FOR was recorded by 10 countries, with a total of 4859 thaws, 4049 transfers, 1235 pregnancies and 755 deliveries ( Table I ). The majority (87%) was performed in Italy and Spain.
Intrauterine insemination
The number of IUI laboratories present in the countries was recorded in 2009 for the first time. Only 18 countries reported the figure, with a total of 993 units, 857 of which (86.3%) were reporting to the National Register (Table I) . Moreover, in four countries, the total number of IUI units in the countries was not available, only the number of reporting units. Among the countries reporting deliveries, the mean delivery rate per cycle was 8.9% (8.3 in 2009), with 9.3% (10.4% in 2009) of deliveries being twins and 0.5% (0.7% in 2009) triplet deliveries.
For IUI-D, 38 124 cycles were reported (+ 8889) by 20 countries, the main contributors being Denmark, France, Spain and the UK. The delivery rate per cycle was 13.8% (13.4% in 2009), with multiple delivery rates of 7.9% (10.3% in 2009) for twins and 0.2% (0.5% in 2009) for triplets. ART in Europe, 2010
Data available on outcomes in women ,40 years and 40 years or more are presented in Supplementary data, Tables SXVII and XVIII. The delivery rate associated with IUI-H declined with age (9.0% ,40 versus 3.7% above) and the multiple delivery rates decreased from 8.9 to 5.3% for twins and from 0.6 to 0.0% for triplets.
Similar findings were seen in IUI-D, where delivery rates decreased with age from 14.5 to 7.2%, twin deliveries from 7.9 to 3.8% and triplets from 0.2 to 0.0%.
Sum of fresh and FER ('cumulative') delivery rates
Supplementary data, Table SXIX gives an estimate of a cumulative delivery rate per aspiration in countries performing FER and reporting deliveries.
The calculation, presented as the sum of fresh and FER deliveries with the basic number as the number of aspirations obtained during the same year, is not a true cumulative delivery rate per aspiration, but it shows that the delivery rate (fresh versus cumulative) can increase in the countries reporting the relevant data.
Overall, the increase after inclusion of FER deliveries was from 20.0 to 23.7%, but in some countries the increment was more substantial (Switzerland +9.9%, Finland +12.1%).
In countries where the proportion of aspirations and thawings was .40% the 'benefit' using our definition of cumulative delivery rate was .4%.
Cross-border reproductive care
Only eight countries reported data on patients undergoing cross-border reproductive care (CBRC): Greece, Iceland, Macedonia, Moldova, Poland, Slovenia, Spain and Switzerland. A total of 4867 cycles were reported, 69.4% of which involved IVF/ICSI with the couple's own gametes, 16.0% were oocyte donations and 11.9% were IUI or IVF with semen donation.
Information regarding the countries of origin was very incomplete and not reliable enough to draw any conclusions. The main reason (58%) reported by patients was to seek a higher quality treatment than available in their home countries (data not presented in tables).
Discussion
The present report is the 14th, consecutive annual European report on ART data. Taken together, these reports cover .5 million treatment cycles from 1997 to 2010. Since 2003 also the infants born after ART have been included-nearly 600 000 (Fig. 3) .
As shown in the tables, the method of reporting varies among countries and registries from a number of countries have been unable to provide some of the relevant data, such as initiated cycles and deliveries (Supplementary data, Table SIII ).
It can be argued that as long as data are incomplete and generated through different methods of collection, results should be interpreted with caution. Nevertheless, the findings reported in this paper reveal important trends in practice and outcomes in Europe and give a clear picture of the differences existing among countries.
In comparison with 2009, the number of countries reporting to the ESHRE's EIM Consortium decreased again to 31: Albania, Bosnia, Croatia, Cyprus, Estonia, Latvia and Turkey were not able to contribute data.
Most of the independent European states that have never contributed data are very small countries (Andorra, Armenia, Liechtenstein, Luxemburg, Malta, Monaco, San Marino and Vatican City). Data have never been available from Azerbaijan, Belarus and Kosovo but, overall, EIM has been collecting data from 80% of the European countries for several years (Supplementary data, Table SI ).
The EIM Consortium is working on a method of support for those countries with no existing national registry or with difficulties in providing data again.
In 2010, the coverage of all clinics in countries which provided data was 82.5%, a figure nearly similar to 2009 (85.2%), 2008 (84.5%) and 2007 (86%).
The number of countries with 100% coverage decreased to 16 (21 in 2009, 19 in 2008) .
As in previous years, the lowest reporting rate was from Greece (9 of 50 clinics).
Overall, the number of reported cycles increased by 2.4% since 2009 (+13 009), reaching a total of 550 296 despite fewer countries contributing data.
Clear reasons for this trend are not distinct but the economic situation in some countries could offer a partial explanation.
Elsewhere in the world in 2010, 147 260 cycles were reported from the USA (CDC, 2012) and 61 774 initiated cycles from Australia and New Zealand (AIHW, 2012) .
As shown in Table I and Supplementary data, Table SIV , the average number of treatment cycles per million inhabitants in the countries with 100% coverage was 1221 and 6258 per million women of reproductive age (15 -45 years) . Data for inhabitants are coming from the www.census.gov webpage.
This number varied hugely among countries, with the highest figures from Denmark (2883), Iceland (2594) and Belgium (2736) and the lowest from Hungary (557).
An even better way to define the availability of ART is to use women of reproductive age as the denominator, which eliminates the impact of age differences across the countries. Using this denominator, there were also striking differences in the number of ART cycles per million women of reproductive age, ranging from 2703 cycles in Hungary to 17 701 in Slovenia, 17 669 in Denmark and 14 494 in Belgium. Countries able to provide over 8000 cycles per million women of reproductive age and over 1700 cycles per million inhabitants were the Czech Republic, Finland, Norway, Slovenia and Sweden.
Overall, the highest availability was reported by Slovenia and the Nordic countries. Finally, the percentage of newborns conceived through ART varied from 0.6% in Moldova to 5.9% in Denmark (Table II and Supplementary data, Table SIV ).
The pregnancy rate per aspiration remained relatively stable with an ongoing small increase compared with the previous year: 29.2% for IVF (2009 28.9%, 2008 28.7%) and for ICSI 28.8% (2009 28.5%, 2008 28.7%) .
However, the pregnancy rate per thawing has increased steadily since 2008 (19.3 in 2008, 20.9 in 2009 and 20.3 in 2010) , this improvement could be related to the incorporation of vitrification in the embryology laboratory.
Delivery rates per aspiration and per transfer (22.4 and 25.5% for IVF and 21.1 and 23.5% for ICSI, respectively) showed a marginal increase, compared with figures from 2009 (20.6 and 23.0% for IVF and 19.3 and 21.5% for ICSI, respectively) and 2008 (21.2 and 24.3% for IVF and 20.4 and 22.7% for ICSI, respectively).
The delivery rate per thawing for FER of 14.1% also indicates a small increase (13.3% in 2009 and 13.7% in 2008) but this indicator of outcome may be always strongly influenced by the missing data on deliveries.
After a decrease in 2009 the proportion of ICSI versus conventional IVF procedures showed a marginal increase compared with data from the previous year and is now on the level of 2007 (Fig. 1) . The figure is likely to have been driven by the absence of data from Turkey, a country with a very high proportion of ICSI cycles (98%) in 2008. Table I demonstrates a marked variation in the relative proportions of IVF and ICSI within Europe, and the difference seems to have a geographic distribution.
In several countries from northern and eastern Europe (Denmark, Finland, Iceland, Ireland, Kazakhstan, Lithuania, Romania, Russia, Sweden and The Netherlands), IVF remains the dominant technology; in contrast, in most countries from western and central Europe (Germany, Italy, Spain, Austria and Switzerland) ICSI was used in 75% of cases.
In Australia and New Zealand, 67.3% of all cycles used ICSI in 2010 and in the USA the corresponding figure was 74.0%, reflecting a uniform trend throughout the world in performing ICSI in the majority of the cycles.
The marked increase in the use of ICSI cannot be explained by a similar increase in male infertility but rather by a more liberal use of this technique in cases with mixed infertility, unexplained infertility, mild male factor infertility, low oocyte number and fertilization failures (Jain and Gupta, 2007; Nyboe Andersen et al., 2008) . This is, however, unlikely to fully account for the observed differences, which can only be explained by differences in professional strategy, clinical decision-making and economic requirements.
In the USA, 53% of ICSI cycles were performed in couples without a clear diagnosis of male factor infertility (CDC, 2012) .
Overall, in 2010, the number of transfers with three or more embryos (17.6%) was lower compared with 2009 (18.1%) and 2008 (24.4%), while the mean percentage of SETs (intended and not intended) increased from 22.4% in 2009 and 24.2% in 2008 to 25.7%.
The proportion of DET decreased from 57.7% in 2009 to 56.7% (Table III) .
For the second time since 1997, the proportion of three or more embryo transfers was ,20% and the proportion of SETs was higher than that of triple embryos transfers.
The highest proportions of SETs were found in Sweden (73.3%), Finland (67.5%), Belgium (50.4%) and Denmark (45.2%). In contrast, 50% of three or more embryo transfers were reported in Bulgaria, Greece, Italy, Lithuania, Moldova, Montenegro and Serbia.
The EIM reports are unable to discriminate between elective SET (eSET) versus SET in general, but the increase in the number of transfers of one embryo seen in the last years is undoubtedly due to an increase in eSET.
Despite huge differences in embryo transfer policy across countries, the overall trend towards transferring fewer embryos seen over the last 10 years seems to continue.
In comparison with the situation in Europe, data from other registers show that SET was performed in 69.6% of cycles in Australia and New Zealand (AIHW, 2012) and 15.4% in the USA (CDC, 2012) .
Similar observations can be made for the multiple delivery rates. In 2010, the multiple delivery rates (twins + triplets) remained relatively stable compared with previous years: 20.6% in 2010, 20.2% in 2009, 21.7% in 2008, 22.3% in 2007 and 20.8% in 2006 . ART in Europe, 2010
Overall, a remarkable reduction in triplet deliveries over the years is seen (3.6% in 1997 and 1.0% in 2010), but major differences are still evident across countries (Table III) . Some countries registered a high triplet delivery rate like Serbia (5.2%), Bulgaria (2.2%) and Italy (1.9%). Several other countries were able to maintain the triplet deliveries at ≤0.2% (Belgium, Sweden and The Netherlands).
In this context fetal reduction in multiple delivery rates has to be mentioned. In ED the multiple delivery rate is higher than cycles with own egg. SET would reduce the high multiple delivery rate (Clua et al., 2012) .
The twin delivery rate ranged from 5.8% in Sweden to 32.6% in Macedonia.
We have included data describing preterm birth rates according to the number of fetuses in the pregnancy (Supplementary data, Table SXV) , which was completed by 16 countries. The risk of extreme preterm birth (28 weeks) was increased 3-fold for twins and 13-fold for triplets.
The risk of very preterm birth (28-32 weeks) is increased almost 5-fold for twins and 20-fold for triplets.
Fetal reductions are almost always performed in triplet or higher order gestations. Thus, when analyzing the range of triplet delivery rates in different countries, the number of fetal reductions should also be considered. A total of 441 procedures were reported (43 less than in 2008) (Supplementary data, Table SXVI ).
However, the number is likely to be an underestimate since several countries, including large countries, such as Germany and Italy, did not report on this intervention. Without fetal reductions, the proportion of triplet deliveries would have been much higher than the number of recorded triplet deliveries in IVF and ICSI (788 in total).
The delivery rates in Europe remain lower than in the USA, where in fresh non-donor cycles performed in 2010 the delivery rate per aspiration was 33.7% and the delivery rate per transfer was 36.8% (CDC, 2012).
However, outcomes in Europe were very similar to those achieved in Australia and New Zealand, where the delivery rates per transfer in fresh cycles were 23.6 and 20.2% per aspiration (AIHW, 2012) .
Data on deliveries and infants must be considered and compared with some caution because of the difficulties met by several European countries in gathering pregnancy outcome (Supplementary data, Table SXIV) , while the pregnancy loss to follow-up was close to 0% in the annual reports both in the USA and in Australia/New Zealand.
Multiple infant birth rates (twins, triplets or more) point to important differences between the USA (30.3%), Europe (20.6%) and Australia/ New Zealand (7.8%).
With the noticeable decline in the number of embryos transferred and the increasing proportion of FER cycles, the cumulative delivery rate per started cycle may be the most relevant end-point in ART.
However, such a result can only be obtained a few years after the initial oocyte aspiration.
In Supplementary data, Table SXIX , the cumulative delivery rate is presented as the sum of fresh and FER pregnancies obtained in the same calendar year. The method of calculation can be methodologically flawed, but the estimate may be close to the actual figure. In several countries, FER deliveries added substantially to the delivery rates per cycle: Finland (22.7-34.8%), Belgium (15.7-21.0%), Sweden (22.8-31.9%) and Norway (22.9-28.7%), justifying their transfer and freezing policies.
Regarding direct risks of ART, OHSS was recorded only in 0.3% of all stimulated cycles. However, there may be a degree of under-reporting of this complication as the rate varied between 0 and 2.6% in the countries reporting it.
For the ninth consecutive year, the present report includes European data on treatments with IUI-H (176 512 cycles) and IUI-D (38 124), which show an increase compared with 2009 and 2008. Since the inception of IUI data collection, no significant differences have been noted in terms of delivery rates and in the incidence of multiple pregnancies.
In 2009, the EIM Consortium decided to continue to address the phenomenon of CBRC. An optional module was added to the data collection sheets asking for the numbers of CBRC patients, the type of treatment requested, main countries of origin and the reason for travelling abroad. Only a total of 4177 cycles were reported by 6 countries. As in 2008 and 2009, the number was much lower compared with the estimation, based on the CBRC study performed in Europe (Shenfield et al., 2010) : 11 000 -14 000 patients and 25 000 -30 000 cycles per year.
In addition, only incomplete information was reported regarding the countries of origin and reasons for travelling.
In summary, the 14th ESHRE report on ART for Europe shows a continuing moderate expansion in the number of treatment cycles, with more than half a million cycles reported in 2010. The use of ICSI seems to have reached a plateau.
(Multiple) pregnancy and delivery rates after IVF and ICSI remained relatively stable, compared with 2009 and 2008. The number of multiple embryo transfers (three or more embryos) has shown a decline.
